Smart Decisions | G-FINDER Neglected Diseases R&D Report

30 Jan 2025
Impact Global Health

The R&D landscape for neglected diseases shows choices are being made. How do we know if they’re the right ones? A flat line in overall global health R&D funding coupled with an increase in tropical diseases as the planet gets hotter means tough choices are on the agenda. The challenge for funders and policy makers looking to have maximum impact is to understand the context, choose wisely, and find innovative approaches to lower the cost of R&D. The latest G-FINDER report helps you make smart decisions.

  • 63% of global funding came from governments in 2023 - Which is a record low
  • 12% of the global vaccine funding in 2023 is for TB - Up from 5% in 2018
  • 83% of global philanthropic investment in 2023 - Is from the Gates Foundation

Tough choices in neglected disease R&D require smart decisions

Advances in malaria, TB, and snakebite products show the impact of well-targeted investments. Declines in funding for pneumonia and meningitis vaccines, for example, reflect a smart strategic shift following successful product launches. But climate change is amplifying the disease burden and driving outbreaks, like dengue, leishmaniasis and diarrhoeal diseases, in new parts of the world. Progress in tackling some diseases, like HIV, is at risk of backsliding despite significant unmet needs. Read the 2024 G-FINDER Neglected Disease R&D report to get to grips with the landscape, and to equip yourself to make smart decisions.

Research Financing